FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225471569> ?p ?o ?g. }

• W4225471569 abstract "Background Pyrotinib, a small-molecule tyrosine kinase inhibitor, has been investigated as a component of neoadjuvant therapy in phase 2 trials of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This study aimed to evaluate the effectiveness and safety of pyrotinib-containing neoadjuvant therapy for patients with HER2-positive early or locally advanced breast cancer in the real-world setting. Methods Data of 97 patients with HER2-positive breast cancer from 21 centers across China treated with pyrotinib-containing neoadjuvant therapy were reviewed. Neoadjuvant therapy consisted of taxane/carboplatin/trastuzumab plus pyrotinib (TCbH+Py, 30 [30.9%]), anthracycline/cyclophosphamide followed by taxane/trastuzumab plus pyrotinib (AC-TH+Py) or taxane followed by anthracycline/cyclophosphamide/trastuzumab plus pyrotinib (T-ACH+Py, 29 [29.9%]), taxane/trastuzumab plus pyrotinib (TH+Py, 23 [23.7%]), and other pyrotinib-containing neoadjuvant treatment (15 [15.5%]). The primary outcome was breast pathological complete response (bpCR, ypT0/is) rate. Secondary outcomes included total pathological complete response (tpCR, ypT0/is ypN0) rate, objective response rate (ORR), and the incidence of preoperative adverse events. Results The ORR of pyrotinib-containing neoadjuvant therapy was 87.6% (85/97). The bpCR and tpCR rates were 54.6% (95% confidence interval [CI], 44.2%-64.7%) and 48.5% [95% CI, 38.2%-58.8%], respectively. The most common grade 3 or 4 treatment-related adverse events included diarrhea (15 [15.5%]), decreased hemoglobin (nine [9.3%]), and decreased neutrophil count (eight [8.2%]). No treatment-related deaths occurred. Conclusion Pyrotinib-containing neoadjuvant therapy for patients with HER2-positive early or locally advanced breast cancer shows favorable effectiveness with manageable toxicity in the real-world setting. Trastuzumab plus pyrotinib may be a novel option of dual HER2-targeted blockade." @default.
• W4225471569 created "2022-05-05" @default.
• W4225471569 creator A5008204710 @default.
• W4225471569 creator A5013475095 @default.
• W4225471569 creator A5017212387 @default.
• W4225471569 creator A5031666815 @default.
• W4225471569 creator A5033884558 @default.
• W4225471569 creator A5041509753 @default.
• W4225471569 creator A5047368693 @default.
• W4225471569 creator A5047774041 @default.
• W4225471569 creator A5066926559 @default.
• W4225471569 creator A5069842224 @default.
• W4225471569 creator A5086854382 @default.
• W4225471569 creator A5090253931 @default.
• W4225471569 date "2022-04-07" @default.
• W4225471569 modified "2023-10-18" @default.
• W4225471569 title "Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis" @default.
• W4225471569 cites W2011977835 @default.
• W4225471569 cites W2044702943 @default.
• W4225471569 cites W2055235037 @default.
• W4225471569 cites W2063874882 @default.
• W4225471569 cites W2109529198 @default.
• W4225471569 cites W2111578514 @default.
• W4225471569 cites W2125239609 @default.
• W4225471569 cites W2126249310 @default.
• W4225471569 cites W2162982444 @default.
• W4225471569 cites W2283816551 @default.
• W4225471569 cites W2531506996 @default.
• W4225471569 cites W2560406314 @default.
• W4225471569 cites W2613098450 @default.
• W4225471569 cites W2768649895 @default.
• W4225471569 cites W2899659781 @default.
• W4225471569 cites W2947067095 @default.
• W4225471569 cites W2969604985 @default.
• W4225471569 cites W2981669117 @default.
• W4225471569 cites W2994601580 @default.
• W4225471569 cites W3000643213 @default.
• W4225471569 cites W3043096450 @default.
• W4225471569 cites W3044204256 @default.
• W4225471569 cites W3090147133 @default.
• W4225471569 cites W3104822654 @default.
• W4225471569 cites W3122861570 @default.
• W4225471569 cites W3127064904 @default.
• W4225471569 cites W3202365988 @default.
• W4225471569 cites W4207036602 @default.
• W4225471569 cites W4210303609 @default.
• W4225471569 cites W4211032970 @default.
• W4225471569 cites W4214501338 @default.
• W4225471569 cites W4243460686 @default.
• W4225471569 doi "https://doi.org/10.3389/fonc.2022.855512" @default.
• W4225471569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35463365" @default.
• W4225471569 hasPublicationYear "2022" @default.
• W4225471569 type Work @default.
• W4225471569 citedByCount "3" @default.
• W4225471569 countsByYear W42254715692022 @default.
• W4225471569 countsByYear W42254715692023 @default.
• W4225471569 crossrefType "journal-article" @default.
• W4225471569 hasAuthorship W4225471569A5008204710 @default.
• W4225471569 hasAuthorship W4225471569A5013475095 @default.
• W4225471569 hasAuthorship W4225471569A5017212387 @default.
• W4225471569 hasAuthorship W4225471569A5031666815 @default.
• W4225471569 hasAuthorship W4225471569A5033884558 @default.
• W4225471569 hasAuthorship W4225471569A5041509753 @default.
• W4225471569 hasAuthorship W4225471569A5047368693 @default.
• W4225471569 hasAuthorship W4225471569A5047774041 @default.
• W4225471569 hasAuthorship W4225471569A5066926559 @default.
• W4225471569 hasAuthorship W4225471569A5069842224 @default.
• W4225471569 hasAuthorship W4225471569A5086854382 @default.
• W4225471569 hasAuthorship W4225471569A5090253931 @default.
• W4225471569 hasBestOaLocation W42254715691 @default.
• W4225471569 hasConcept C121608353 @default.
• W4225471569 hasConcept C126322002 @default.
• W4225471569 hasConcept C143998085 @default.
• W4225471569 hasConcept C2776694085 @default.
• W4225471569 hasConcept C2776755627 @default.
• W4225471569 hasConcept C2776802502 @default.
• W4225471569 hasConcept C2777511904 @default.
• W4225471569 hasConcept C2778292576 @default.
• W4225471569 hasConcept C2779786085 @default.
• W4225471569 hasConcept C530470458 @default.
• W4225471569 hasConcept C71924100 @default.
• W4225471569 hasConceptScore W4225471569C121608353 @default.
• W4225471569 hasConceptScore W4225471569C126322002 @default.
• W4225471569 hasConceptScore W4225471569C143998085 @default.
• W4225471569 hasConceptScore W4225471569C2776694085 @default.
• W4225471569 hasConceptScore W4225471569C2776755627 @default.
• W4225471569 hasConceptScore W4225471569C2776802502 @default.
• W4225471569 hasConceptScore W4225471569C2777511904 @default.
• W4225471569 hasConceptScore W4225471569C2778292576 @default.
• W4225471569 hasConceptScore W4225471569C2779786085 @default.
• W4225471569 hasConceptScore W4225471569C530470458 @default.
• W4225471569 hasConceptScore W4225471569C71924100 @default.
• W4225471569 hasLocation W42254715691 @default.
• W4225471569 hasLocation W42254715692 @default.
• W4225471569 hasLocation W42254715693 @default.
• W4225471569 hasOpenAccess W4225471569 @default.
• W4225471569 hasPrimaryLocation W42254715691 @default.
• W4225471569 hasRelatedWork W1807805395 @default.
• W4225471569 hasRelatedWork W2013223170 @default.
• W4225471569 hasRelatedWork W2020150632 @default.

• next